Clinical trial · Interventional
64Cu/68Ga Labelled EB-ss-CPT PET/CT Scan in Colorectal Cancer
NCT05891028CI-TRIAL-00067002unknownEarly Phase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Positron labeled camptothecin based PET imaging is a new imaging technique that uses positron isotopes such as 68Ga/64Cu for PET/CT (MR) imaging. It is expected to have significant clinical significance in staging and detecting primary and metastatic head and neck cancer, oral cancer, and colorectal cancer tumors.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colorectal Cancer | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 64Cu-EB-ss-CPT | Drug | — | UNRESOLVED |
| 68Ga-EB-ss-CPT | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- 68Ga-EB-ss-CPT PET/CT scan
- description
- 68Ga-EB-ss-CPT PET/CT scan Dosimetry study about 6 patients were injected with 3 (MBq) per kilogram body weight of 68Ga-EB-ss-CPT PET/CT in one dose intravenously and underwent wholebody scan at 5min#30min#60min#120min#240min, then analysis of dosimetric distribution ofradiopharmaceuticals in human body by HERMES software.
- interventionNames
- Drug: 68Ga-EB-ss-CPT
- type
- EXPERIMENTAL
- label
- 64Cu-EB-ss-CPT PET/CT scan
- description
- 64Cu-EB-ss-CPT PET/CT scan Dosimetry study about 6 patients were injected with 2 (MBq) per kilogram body weight of 64Cu-EB-ss-CPT PET/CT in one dose intravenously and underwent wholebody scan at 30min#8h#12h#24h#48h, then analysis of dosimetric distribution ofradiopharmaceuticals in human body by HERMES software.
- interventionNames
- Drug: 64Cu-EB-ss-CPT
Primary outcomes (2)
Eligibility
Eligibility (as posted)
- Sex
- All
- Maximum age
- 85 Years
Show eligibility criteria text
Inclusion Criteria: * In the near future (within 2 months), patients who plan to undergo puncture biopsy or undergo tumor surgical treatment or are clinically highly suspected of cancer (including primary and tumor recurrence and metastasis) * Able to understand and voluntarily sign informed consent forms, with good compliance Exclusion Criteria: * Severe abnormalities in liver and kidney function * Suffering from claustrophobia or other mental illnesses * Pregnant, pregnant, and lactating women
References
Publications (0)
Data not yet available
No reference posted for this study.